Nonclinical toxicity testing of chemicals and chemically-derived small molecule pharmaceuticals as well as biotechnology-derived large molecule pharmaceuticals plays a critical role in risk assessment and risk mitigation. While toxicity testing of chemicals aims to identify and manage hazards to human health and the environment following intended or accidental exposure, pharmaceutical toxicity testing forms a critical part of the risk-benefit assessment which balances the intended beneficial effects on the patient health against observed toxicities and potential adverse effects.
Journal of clinical toxicology is considers toxicity testing as a major issue in clinical toxicology and thus publishes the recent updates in the field of toxicity testing. Since this is a major issue to be considered with all seriousness, we would like to reveal this research to the scientific community. Initially the research related to clinical and pre-clinical testing was not revealed as articles. But now the trend has been changed and adverse drug reactions during drug toxicology testing is being reported as research findings as well as individual cases.
Last date updated on January, 2021